Sofgen: ANI Pharmaceuticals, Sofgen Announce FDA Approval of Nimodipine 30mg Capsules

ANI Pharmaceuticals, Inc. ("ANI") today announced that its ANDA collaboration partner Sofgen has received approval from the U.S. Food and Drug Administration (FDA) of the Abbreviated New Drug Application (ANDA) for Nimodipine 30mg Capsules. Trailing twelve-month sales for the product are $25 million, according to IMS Health, with two current competitors. ANI and Sofgen expect to begin shipping to customers this year. Read more about ANI Pharmaceuticals, Sofgen Announce FDA Approval of Nimodipine 30mg CapsulesComments